325 studies found for:    biogen | biogen
Show Display Options
Rank Status Study
21 Completed Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Condition: Multiple Sclerosis
Intervention: Drug: low immunogenic interferon-beta-1a
22 Completed Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
23 Completed Open-Label Natalizumab Safety Extension Study
Condition: Multiple Sclerosis
Intervention: Drug: Natalizumab
24 Suspended Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Oligoastrocytoma, Mixed;   Gliosarcoma
Intervention: Genetic: Interferon-beta
25 Terminated Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Lumiliximab + FCR;   Drug: FCR
26 Withdrawn BIIB014 Phase 2a Monotherapy
Condition: Parkinson's Disease
Interventions: Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.;   Drug: placebo
27 Completed BG9928 in Subjects With Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: BG9928
28 Completed Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
29 Not yet recruiting Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers
Condition: Multiple Sclerosis
Interventions: Drug: peginterferon beta-1a;   Drug: Rebif
30 Recruiting Observational Study of Tysabri® in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus (JCV) Antibody Negative Participants
Condition: Relapsing-Remitting Multiple Sclerosis
31 Not yet recruiting Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Interferon Beta;   Drug: BIIB017 (Peginterferon beta-1a)
32 Not yet recruiting Plegridy™ Observational Program
Condition: Relapsing Forms of Multiple Sclerosis
Intervention: Drug: peginterferon β-1a
33 Recruiting Multiple Dose Study of BIIB037 (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: BIIB037 (recombinant, fully human anti-Aβ IgG1 mAb);   Drug: Placebo
34 Not yet recruiting Immunogenicity and Safety Study of Natalizumab (BG00002) Administered to Participants With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple Sclerosis
Intervention: Drug: BG00002 (natalizumab)
35 Not yet recruiting Gastrointestinal Tolerability Study Of Dimethyl Fumarate (DMF) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: BG00012
36 Recruiting PK and PD Study of Natalizumab in Pediatric Subjects With RRMS
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Biological: Natalizumab
37 Not yet recruiting Natalizumab (BG00002) as an Efficacy Switch in Subjects With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies
Condition: Relapsing Multiple Sclerosis
Intervention: Drug: Natalizumab
38 Not yet recruiting Efficacy and Safety Study of Prolonged-Release Fampridine in Subjects With Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: BIIB041 (Prolonged-release fampridine);   Other: Placebo
39 Not yet recruiting Real-world Outcomes on Tecfidera® (BG00012, Dimethyl Fumarate) Post-Tysabri® (BG00002, Natalizumab)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BG00002 (Natalizumab);   Drug: BG00012 (dimethyl fumarate)
40 Recruiting A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
Conditions: Multiple Sclerosis, Remittent Progressive;   Multiple Sclerosis, Primary Progressive;   Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: fampridine (BIIB041)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years